Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CG1-H52P6 | Human | Human CGRPR&RAMP1 Full Length Heterodimer Protein (VLP) |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Atogepant | MK-2918; MK-8825; AGN-241689; MK-8031 | Approved | Merck & Co Inc | Qulipta, Aquipta, QULIPTA | United States | Migraine Disorders | Abbvie Inc | 2021-09-28 | Migraine Disorders | Details |
| Ubrogepant | MK-1602 | Approved | Merck Sharp & Dohme Corp | Ubrelvy | United States | Migraine Disorders | Abbvie Inc | 2019-12-23 | Migraine Disorders | Details |
| Zavegepant | BHV-3500; BMS-742413; BMS-742413-03; PF 07930207 | Approved | Bristol-Myers Squibb Company | ZAVZPRET | United States | Migraine Disorders | Pfizer Inc | 2023-03-09 | Migraine Disorders; Coronavirus Disease 2019 (COVID-19); Migraine with Aura; Asthma; Migraine without Aura | Details |
| Erenumab | I5I8VB78VT (UNII code); AMG-334 | Approved | Amgen Inc | Aimovig, 安默唯 | United States | Migraine Disorders | Amgen Inc | 2018-05-17 | Migraine Disorders; Headache Disorders, Primary; Headache; Trigeminal Autonomic Cephalalgias; Brain Injuries, Traumatic; Rosacea; Brain Diseases; Hot Flashes; Angina, Stable; Temporomandibular Joint Disorders; Post-Concussion Syndrome; Trigeminal Nerve Diseases; Post-Traumatic Headache; Cluster Headache | Details |
| Rimegepant sulfate | BHV-3000; BMS-927711 | Approved | Bristol-Myers Squibb Company | Nurtec Odt, 乐泰可 | United States | Migraine Disorders | null, Pfizer Inc | 2020-02-27 | Migraine Disorders; Trigeminal Neuralgia; Nasal Polyps; Psoriasis; Temporomandibular Joint Disorders; Sinusitis | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| TNX-2900 | TNX-2900 | Phase 2 Clinical | Tonix Pharmaceuticals Holding Corp | Prader-Willi Syndrome | Details |
This web search service is supported by Google Inc.
A-Z
